The disease

There are not specifically approved treatments for NASH; however off-label treatments are currently used. Being the need of an approved therapy the main unmet need.


Accumulation of fat in the liver is the first and reversible event that occurs within the physio-pathological progression from a healthy liver to NASH. This abnormal and significant lipid accumulation in the organ, referred to hepatic steatosis, Simple Steatosis (SS) or (Non-Alcoholic) Fatty Liver (NAFL), is the consequence of a dramatic increase of free fatty acid fluxes into the organ.

GlobalData reported about 70M prevalent cases of NASH in the 7 major markets (MM) in 2019. The global NASH market accounted for 174.8M$ in 2021 and it is expected to reach a value of 27$ by 2031 showing a growth trend in the following years with a CAGR of 58%. Major players in these areas have been identified.